• Violent crimes in the U.S. occur every 24.6 seconds, and property crime occurs every 4.1 seconds
• There are over 320 million people in the U.S., with only two million+ law enforcement and security professionals to protect them
• Knightscope’s autonomous security robots are currently in operation across five U.S. time zones, with over one million hours in the field
• The K1 is an award-winning ASR whose achievements were recognized with the 2018 Security Today New Product of the Year

Knightscope, a leader in the development of autonomous security capabilities, is reimagining public safety to make the United States the safest country in the world, through an innovative line of Autonomous Security Robot (“ASR”) products that combine self-driving technology, robotics, and artificial intelligence (https://ibn.fm/RLzlv). In the United States, a violent crime occurs every 24.6 seconds and a property crime every 4.1 seconds, according to Knightscope statistics. Moreover, it is estimated that there are only a little over two million law enforcement and security officers across the country to help and protect a population of over 300 million people across all 50 states. Knightscope’s ASRs are helping to bridge the gap, offering valuable assistance and coverage and supporting law enforcement personnel to do their jobs more effectively. The ASRs are typically used for patrolling and peacekeeping, as a means of physical deterrence by providing a visible, force multiplying, physical security presence to help protect assets and deter crime. However, they have also taken a more active role in fighting crime by assisting law enforcement and security with the arrests of suspects in crimes that range from armed robbery to hit-and-run accidents. More information about the work Knightscope is doing to fight crime is available at www.Knightscope.com/crime. Knightscope’s current offering includes three ASR models being utilized across five time zones in the United States: K1, K3, and K5. Recognized for its achievements with the 2018 Security Today New Product of the Year Award, K1 is a stationary machine that can be used in indoor or outdoor environments and is suitable for use in a wide range of spaces including parking structures, lobby and reception areas, high-risk areas, help or assistance points, transportation shuttle stops and more. K3 is an indoor ASR that moves at speeds up to three miles per hour. It runs on its own 24/7/365 and can autonomously recharge itself without human intervention. It is the smart eyes and ears that cover many areas without the need for monotonous patrols. The K3 is suitable for environments such as malls, warehouses lobbies or offices, hospitals, airports, casinos, etc. K5 is primarily used outdoors, even though it does have the capability of being used indoors. It features 24/7/365 operation and the ability to recharge autonomously without human intervention. This ASR model is best suited for large outdoor spaces and moves up to three miles per hour. The K5 has been operated for nearly one million hours in the field, including three winters. The K5 can be used in many large-spaced venues, including but not limited to hospitals, police departments, municipalities, airports, stadiums, manufacturing facilities, corporations and others. All three of the ASR models feature the Knightscope Securities Operations Center (KSOC), which features force-multiplying physical deterrence, facial recognition, 360-degree HD video streaming, automatic license plate recognition, thermal anomaly detection, and so much more. Knightscope has plans to develop other security solutions in the near future and is already in the process of raising additional growth capital while also preparing for a potential public listing. The company has already reserved the NASDAQ ticker symbol ‘KSCP’ and you can learn more reading the blog “Are You Going Public?!” (https://ibn.fm/78rrz). Since its foundation in 2013, Knightscope has raised more than $70 million to build all of its technology from scratch and is now backed by more than 16,000 investors and four major corporations. For more information, visit the company’s website at www.Knightscope.com. Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• Pure Extracts carried out its initial oil extraction, distillation trials in early November, plans to commence extraction tolling services in December
• Once Sales License is obtained from Health Canada, the Company plans to begin marketing its own ‘Pure Pulls’ branded cannabis derived product range
• Pure Extracts will simultaneously seek to market Company’s white-labelling prowess, offering oil extraction capabilities to Licensed Producers currently operating in cannabis space
• Company also announced its interest in joining functional mushroom sector, with its first products set to be launched in 1Q2021
• Separately, Pure Extracts named Dwight Duncan to its Board of Directors

Pure Extracts Technologies (CSE: PULL), a plant-based extraction company focused on the cannabis, hemp, and functional mushroom sectors, has seen its business operations scale to new heights following the award of its Standard Processing license from Health Canada on September 25, 2020. The receipt of the license enabled Pure Extracts to begin producing THC and CBD extracts in its purpose-built extraction facility located near Whistler, British Columbia, whilst adhering to EU Good Manufacturing Practices (“GMP”)—a process which ensures that molecules will be extracted to the highest possible quality. On November 4, Pure Extracts ran the first oil extraction and distillation trial under its license, in the wake of a six-week process during which the Company commissioned the equipment required for commercial production. The occasion marked the initial step of a trial required for the Company to apply for its Sales License with Health Canada, following which Pure Extracts will seek to begin marketing its own-branded Pure Pulls and Pure Chews products. Simultaneously, the Company is also set to begin its extraction tolling business in December – a process through which biomass is converted into THC and CBD oil. Pure Extracts is set to specialize in the production of full-spectrum oil (“FSO”), a product which contains all the cannabinoids and other chemicals which naturally occur in the plant prior to extraction. With demand for full spectrum oil witnessing an exponential increase as of late, the Company revealed that it had bid on a number of contracts and anticipated capturing a meaningful amount of business by the first quarter of next year (https://ibn.fm/WBoiy). Pure Extracts has sought to combine its oil extraction enterprise – which will consist of the Company’s extraction tolling business, white-label product manufacturing as well as the marketing of its own branded products with a new venture into the functional mushroom space. Functional mushrooms have increasingly been identified as a new ‘wonder’ product within the wellness space, gaining popularity for both their apparent health benefits and ability to help slow or even reverse certain diseases. The Company is exploring strategic relationships with established players in the North American sector and intends to launch its initial product range in the first quarter of 2021 through an online portal which is currently under development. Pure Extracts has sought to combine its growing business prospects with a simultaneous focus on strengthening its management and corporate governance functions. The Company announced its appointment of Dwight Duncan, a strategic advisor to Canadian law firm McMillan LLP and former Member of the Ontario legislature where he served as Deputy Premier and Minister of Finance, to its Board of Directors. “We are pleased to welcome Dwight Duncan to the Board of Pure Extracts” noted Chief Executive Officer Ben Nikolaevsky. “Dwight has tremendous experience in both government regulatory affairs and corporate finance, and we are looking forward to working closely with him as we build Pure Extracts into a preeminent global extraction company” (https://ibn.fm/clZv2). For more information, visit the company’s website at www.PureExtractsCorp.com. NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• Closed design of Streamway(R) System provides safety from potential hazards of drips and spills during endoscopy, radiology, cystoscopy, urology procedures
• The Streamway(R) System reduces costs, minimizes environmental impact of 50 million potentially disease-infected canisters disposed into landfills
• POAI’s Skyline Medical sells 8 Streamway(R) Systems to large university hospital in Virginia, 15 sold halfway into Q3 2020

In the age of COVID-19, the need for sanitation and safety during hospital procedures has reached an all-time high. Health professionals have reported an inhibited level of performance due to a lack of protection, comfort, and increased fatigue during surgery (https://ibn.fm/87UEr). Sanitary disposal systems, able to offer maximum protection to healthcare workers, have become incredibly necessary—and companies like Predictive Oncology are answering the call. Produced by Skyline Medical, a subsidiary of Predictive Oncology (NASDAQ: POAI), the patented Streamway(R) System features an entirely closed design, ensuring that medical professionals are safe from the potential hazards of drips and spills. It’s the first FDA-cleared direct-to-drain fluid disposal system that is designed specifically for medical applications such as endoscopy, radiology, cystoscopy and urology procedures. The proprietary system automates the collection, measurement and disposal of potentially infectious waste that includes blood and irrigation fluids. By connecting directly to a facility’s plumbing system, the Streamway(R) System has the potential to change the way healthcare facilities manage fluid disposal by minimizing human intervention and increasing compliance with Occupational Safety and Health Administration (“OSHA”) and other regulatory agency safety guidelines. Along with addressing safety concerns, the use of the Streamway(R) System reduces costs and minimizes environmental impacts by eliminating carts, evacuated bottles and the approximately 50 million potentially disease-infected canisters that go into landfills each year in the United States. COVID-era concerns have increased sales of the Streamway(R) System in 2020, with 15 sales in Q3 (including eight to a large university hospital organization in Virginia) in addition to sales throughout the world through direct sales and distributor partners. Along with Skyline, POAI leverages the synergies of its other three wholly-owned subsidiaries – Helomics, TumorGenesis, and Soluble Biotech – to fulfill its mission of bringing precision medicine to the diagnosis of cancer. Besides the Streamway(R) System, POAI’s portfolio assets also include an AI-enhanced “smart” patient-derived tumor profiling platform, an in-house bioinformatics artificial intelligence (AI) platform, and a data-based approach to growing patient-specific tumors in a lab for the development of personalized treatment options. The importance of precision medicine in cancer therapeutics has grown substantially, driven specifically by data-based predictive models of tumors and their responses to pharmaceutical treatments. Modeling various tumors can be both time and data-intensive, requiring five to seven years of clinical evaluation and observation to produce both historical and outcome data. To that end, POAI has a significant competitive advantage through its vast collection of tumors and their related data, in addition to the company’s ability to access associated outcome data. The application of AI to its trove of more than 150,000 tumors assists oncologists in providing individualized patient treatments while driving forward the development of new targeted therapies in collaborations with pharmaceutical companies. POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow. For more information, visit the company’s website at www.Predictive-Oncology.com NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• The company plans to add another study arm to its ongoing Phase 2b OPTION 2 clinical study which currently tests delayed release capsules
• If it receives FDA approval, AzurRx would be able to identify the optimal delivery method for its drug candidate MS1819 without significant extra costs or delays
• Enrollment in this arm of the study could begin as early as December 2020

AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, has submitted a protocol amendment request to the U.S. Food and Drug Administration that would allow it to test immediate release capsules of its exocrine pancreatic insufficiency drug candidate MS1819. According to a company press release, if the amendment is approved, AzurRx would modify its current Phase 2b OPTION 2 trial of MS1819 in cystic fibrosis patients to add a study arm that uses immediate release capsules (https://ibn.fm/Ws66z). The existing arm of the study uses delayed release capsules. This would allow AzurRx to compare data from both arms to determine the best delivery method for its lead product. “As this trial progresses, we believe there may be significant clinical value in adding a study arm that uses our immediate release capsules. Our intention is to identify the optimal delivery method and potentially provide additional scientific support and optionality for MS1819,” AzurRx Chief Medical Officer Dr. James Pennington said. The addition of a new arm would not impact the overall trial objectives, endpoints and statistical analysis of the Phase 2b OPTION 2 trial. “We are pleased to announce that our OPTION 2 trial is well ahead of schedule and almost fully enrolled without any safety issues being observed,” Dr. Pennington added. He also explained that determining appropriate dosage and delivery method is an important goal for any Phase 2 clinical trial, along with testing for safety and efficacy, before entering a Phase 3 program. He added that if the amendment is accepted by the FDA, AzurRx expects to begin enrollment into the new study arm as soon as December 2020. AzurRx CEO James Sapirstein also said that the protocol amendment is a unique opportunity for the company to acquire valuable additional clinical data with no significant delays in the study timeline and no significant increase in overall costs. The Phase 2b OPTION 2 trial consists of testing MS1819 doses in enteric capsule form with two concentrations: 2240mg and 4480mg. Initial results from the study indicated that the MS1819 non-porcine recombinant lipase is well tolerated at both dose levels and produces no adverse effects. AzurRx is also conducting a Phase 2 cystic fibrosis combination trial, using MS1819 together with porcine pancreatic enzyme replacement therapy (“PERT”), the current standard of care. This study uses daily PERT doses in combination with different MS1819 dosages (700mg, 1120mg and 2240mg) and results made available so far have shown clinically meaningful improvements in subjects, with no adverse safety events. According to Sapirstein, the company remains on target to release to line data for its Phase 2b trial in the first quarter of 2021. Top line data for the combination trial is expected in the second quarter. Pending the Phase 2b trial outcome, the company will initiate a Phase 3 trial in cystic fibrosis and to this end, it has already identified and signed a binding letter of intent with a potential partner for the development and production of MS1819 for the study. Under the agreement, Asymchem, a leading global contract development and manufacturing service provider, will implement fermentation, verify protein expression, and fine-tune the technology for MS1819 production to help AzurRx optimize manufacturing and prepare for commercialization (https://ibn.fm/HJwT4). AzurRx is determined to develop MS1819 as a safer alternative to porcine pancreatic enzyme replacement therapy, significantly reducing the pill burden of cystic fibrosis patients. The company believes that due to its safety and efficacy, its proposed therapy has the potential to improve the quality of life and help achieve healthier nutrition for many patients suffering from severe exocrine pancreatic insufficiency, including those with cystic fibrosis, chronic pancreatitis, pancreatectomy, and other indications. For additional information, visit www.AzurRx.com or contact the following: AzurRx BioPharma, Inc. Phone: (646) 699-7855 info@azurrx.com NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX

• CNS Pharmaceuticals wants to obtain FDA authorization for an Investigational New Drug application for drug candidate Berubicin, a novel treatment for Glioblastoma Multiforme
• Company believes it’s on track to start in Q1 2021 a potentially pivotal Phase II Berubicin trial with adult GBM patients who have failed their primary treatment for the disease
• Separately, a Phase II adult trial and a first-ever Phase I pediatric trial are slated to begin in 2021 in Poland in collaboration with sub-licensee partner, WPD Pharmaceuticals
• Members of CNS’s management team attended A.G.P.’s Virtual Health Symposium, meeting 1-on-1 with investors

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, recently announced that it has filed an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for its lead drug candidate Berubicin. This application has been accepted for review (https://ibn.fm/6NnwH). Berubicin is proposed for the treatment of Glioblastoma Multiforme (“GBM”), an aggressive form of brain cancer currently considered incurable, and may prove beneficial in treating other central nervous system malignancies. Since gaining the rights to Berubicin, and securing from Reata Pharmaceuticals, Inc. (NASDAQ: RETA) the Phase 1 trial data and assets, CNS has worked diligently to complete the requirements to bring the drug to trial. John Climaco, CEO of CNS Pharmaceuticals, Inc., made a statement about the IND filing and how the tireless efforts of the team during the last year have helped reach this important milestone. “Our laser focus from the beginning has been to start the next phase of the investigation of Berubicin for the treatment of this deadly disease as quickly as possible,” he added. The company believes it is well positioned to execute its plan and initiate a potentially pivotal Phase II trial for Berubicin in Q1 2021 beginning in the United States and expanding to a global trial. The Phase II Berubicin trial that is currently planned in Q1 2021 will evaluate the efficacy of Berubicin in patients with GBM who have failed primary treatment for the disease. Results will be compared with the current second-line standard of care. The trial will be executed with a 2 to 1 randomization of the participating 243 patients to Berubicin or Lomustine (as standard of care). This trial could potentially provide data to the FDA needed for approval of an expedited pathway for further development or approval. CNS Phamaceuticals, in collaboration with sublicensee partner WPD Pharmaceuticals (CSE: WBIO) (FSE: 8SV1), is preparing two other clinical trials for Berubicin in Poland. The two studies include a Phase II trial in adults (set to begin in February 2021) and the first-ever Phase I trial for pediatric patients (scheduled to start later in 2021) (https://ibn.fm/p1zJ8). The IND announcement came a few days before CNS management members attended A.G.P.’s Virtual Healthcare Symposium that took place Thursday, November 19, 2020. The virtual event brought together numerous healthcare and biotech companies for one-on-one meetings with investors, engaging panels and discussions with leading healthcare executives and a keynote speaker address (https://ibn.fm/jNkR6). The IND filing and the upcoming clinical trials make Berubicin an interesting opportunity for investors, as CNS believes its novel treatment can fill the current gap in available GBM treatments and help position the company as a market leader in this fast-growing sector. The overall global brain tumor therapeutics market is targeted to reach an estimated $3.4 billion by 2025, from $2.25 billion in 2019, reflecting a CAGR of 7.20% during the forecast period of 2019 to 2025, Market Study Report research shows (https://ibn.fm/SQkrD). Another report estimated that this market would reach $2.74 billion in 2023, registering a CAGR of 11% during the forecast period of 2018 to 2023 (https://ibn.fm/EnB3Q). For more information, visit the company’s website at www.CNSPharma.com NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• With roughly two million current users in Mexico, Innovative Payment Solutions is now shifting focus to the United States, with the implementation of 50 Southern California kiosks planned for Q4 2020
• The company is expanding beyond the kiosks through plans for its own stable coin, IPSI Coin, which will be backed by the U.S. dollar
• Businesses implementing the IPSI Kiosk have the potential to drive additional net revenue and attract new clientele
• The 2018 global digital payment market was estimated at $43.5 billion and is forecast to expand at a CAGR of 17.6% through 2025
• In 2019, IPSI Kiosks processed approximately 4.5 million transactions in Mexico totaling over $17 million

Innovative Payment Solutions (OTCQB: IPSI) is a digital payment technology service company offering cutting-edge solutions for consumers and service providers. It is focused on building a 21st century payment platform based on its proprietary fintech payment architecture. Incorporated in 2015 and headquartered in Northridge, California, the company has spent the last five years perfecting its payment platform through its operations in Mexico, which still facilitate over two million users. IPSI’s new business structure will use the latest technology, including blockchain and an e-wallet, to provide consumers the ability to make payments worldwide. The company’s innovative ecosystem will include multiple devices, such as POS terminals, mobile applications and self-service kiosks, offering alternative payment methods to meet the needs of unbanked and underbanked consumers. IPSI Kiosk Platform The IPSI Kiosk platform strategy aims to provide simple payment solutions and low-cost financial services for consumers and businesses. These kiosks offer access to digital payments for the unbanked and underbanked, allowing for remittance, merchant payments, microloans and other financial services. The kiosk enables new features and transaction modules to be added and implemented easily, leveraging a flexible, open architecture to minimize costs. Current services provided by the kiosks include bill pay and cellphone top-up. Additional features are currently in development, including payday loans, gaming, auto insurance, title loans, lottery, international remittance, a mobile app and an e-wallet. Already linked to Mexico’s largest service providers, the IPSI network is expected to add over 150 services for payment, including mobile networks, cable providers, home lenders, banks and microlenders. In 2019, IPSI’s kiosk network processed roughly 4.5 million transactions in Mexico totaling over $17 million. The company currently has 50 kiosks that it intends to install at retail locations in Southern California. It also plans to deploy kiosks in other states. IPSI Kiosk Channel Value The IPSI Kiosk provides value for businesses and consumers. For businesses, the IPSI Kiosk:

• Serves as an additional revenue source;
• Attracts new traffic and potential customers;
• Offers remote software updates and monitoring, making the kiosks low maintenance;
• Is easy to use, with little need for customer service intervention; and
• Requires minimal staff training and overhead.

For consumers, the IPSI Kiosk:

• Offers a more comfortable alternative for making payments for cash-dependent unbanked individuals and those uncomfortable with online payments and
• Is accessible 24/7 for bill payment services.

The IPSI Kiosk also provides add-on services that further its value proposition for both businesses and consumers. These include second screen and targeted advertisement options, payday loans, check deposits, prepaid cards and checkout services. IPSI Coin IPSI is currently working on plans to launch its own stable IPSI Coin and has retained Horizons Law and Consulting Group to advise on its stable coin creation. The company plans for IPSI Coin to be backed by the U.S. dollar and administered by an independent custodian to ensure transparency and stability. The creation of the coin will enable customers to send payments directly to over 200 service providers in Mexico and transfer funds in a matter of minutes via the self-service kiosks to be implemented in Southern California. “The fintech industry is undergoing a massive shift with the introduction of artificial intelligence, everchanging distribution models, fee diversion and digital payments,” IPSI CEO William Corbett stated in a news release (https://ibn.fm/wwtBV). “We are focused on providing a comprehensive solution in the digital payment arena for those who need it most. Our goal is to provide the millions of unbanked and underbanked as well as banked consumers in California, a cost efficient and convenient method to make payments and remittances with instant settlement.” Digital Payment Market Outlook In 2018, the global digital payment market was estimated at $43.5 billion. It is expected to register a CAGR of 17.6% through 2025, reaching a forecast market size of $132.5 billion, according to Grandview Research (https://ibn.fm/pLTUt). The growth is expected to be led by expanding use of smartphones, e-wallet payment solutions and the introduction of unbanked payment solutions to the market, offering companies such as IPSI significant opportunities for expansion. Management Team William Corbett is the CEO and a Director of IPSI. He has 30 years of experience financing and advising development and growth stage tech and biotech companies. Before IPSI, he was the founder and CEO of California-based Digital Power Lending. Corbett gained experience as a managing director during his time with Paulson Investment Co. and in senior banking and top producer roles at Lehman Brothers and Bear Stearns. He was a co-founder of the San Francisco and PIPE pioneer boutique investment bank, The Shemano Group. He has raised over $2 billion during his extensive career. Andrey Novikov serves as IPSI’s Chief Technical Officer and Chief Operating Officer. He is the former VP of Global Business Development of Qiwi PLC (NASDAQ: QIWI). Leveraging extensive knowledge of the industry, Novikov played a lead role in the development of Qiwi startups in China, Mexico, India, Brazil, Argentina, Chile, Peru and other countries. James W. Fuller holds a Director position at IPSI. He is the former chairman of San Francisco think tank Pacific Research Institute. He is a board member for The International Institute of Education, a member of the Pacific Council for International Policy, and a former member of the Committee of Foreign Relations and the board of trustees of the University of California – Santa Cruz. He is the former Senior Vice President of the New York Stock Exchange and was responsible for corporate development, marketing, regulation oversight, research, corporate listing and public affairs. For more information, visit the company’s website at www.InnovatePaySolve.com. NOTE TO INVESTORS: The latest news and updates relating to IPSI are available in the company’s newsroom at https://ibn.fm/IPSI

• Measurable success achieved in Q3 2020 in key financial, operational, and technical projects
• Revenue increases reported in products and services offerings; balance sheet improved with significant reduction in variable-rate debt
• Q3 total revenue exceeded Q1 and Q2 total revenue combined
• Company reported receipt of 12 pre-orders for the innovative BaroShear K45, which is on track to be released in mid-2021
• Alliance with Leica Microsystems over PBI’s proprietary pressure cycling technology (“PCT”) platform has the potential to accelerate cancer R&D and subsequent drug development using an innovative tumor processing workflow

Pressure BioSciences (OTCQB: PBIO) is a leader in the development, marketing, and sale of proprietary pressure-based instruments, consumables, services, and platform solutions to the worldwide life sciences and other industries. Last week, the Company recently reported its third-quarter financial results and provided a business update, including initial expectations for 2021 (https://ibn.fm/sfRbm). The Q3 2020 Form 10-Q financial report underlines that measurable progress was seen in three important areas: key operational and technical projects; revenue increases in the Company’s products and services offerings; and important structuring improvements in the reduction of arduous, variable-rate convertible debt. According to Pressure BioSciences CEO and President Richard T. Schumacher, the Company achieved impressive results in Q3 compared to the previous two quarters of 2020, which were both negatively impacted by business interruptions caused by COVID-19. The Q3 results have shown a remarkable recovery, with revenue exceeding Q1 and Q2 2020 combined. “Similarly, instrument sales in Q3 2020 exceeded instrument sales in Q1 and Q2 2020 combined, and contracted services revenue for our Ultra Shear Technology(TM) nanoemulsions and BaroFold(TM) biopharmaceutical protein refolding and recovery platforms in Q3 2020 also exceeded revenue for the same services in Q1 and Q2 2020 combined,” Schumacher added. The Company has restructured debt and improved its investment-grade profile. Going into 2020, the Company had approximately $5.4 million in expensive, variable-rate convertible debt. As of the end of September, this had been reduced to $1.7 million through the combination of cash and conversion into common stock at the above-market price of $2.50. The Company also carried a Merchant Cash Advance balance totaling approximately $1.1 million, which was paid down to $0 during the Quarter. Providing other updates and plans for 2021, the Form 10-Q report also mentioned that Pressure BioSciences is on track to launch its innovative BaroShear K45 Nanoemulsification System by mid-2021. Purchase orders for the 12 BaroShear K45 systems the Company plans to manufacture in early 2021 have already been received ahead of the planned mid-2021 commercial release. This novel and proprietary system, based on the Company’s Ultra Shear Technology(TM) (“UST”) patented platform, is designed to revolutionize the processing of immiscible liquid, turning them into water-soluble nanoemulsions. The BaroShear K-45 system was created to revolutionize the processing of immiscible liquids – usually processed into macro/micro emulsions – into high quality, highly profitable nanoemulsions. Emulsions are mixtures of two or more liquids (e.g., oils in water) that typically cannot be blended into each other without the addition of chemicals called emulsifiers (e.g., surfactants). Emulsions are used in thousands of products in everyday use, including food, medical products, pharmaceuticals, nutraceuticals, cosmetics, industrial lubricants, and even cannabis oil extracts (e.g., CBD). Scientific data indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels, and other advantages (such as more reliable dosing control) are better achieved with high quality nanoemulsions. The Company was recently awarded the first United States patent for its proprietary Ultra Shear Technology Platform, as well as a patent for its best-selling and pressure-based consumable device, the PCT MicroPestle. Two UST patents had been previously awarded in China for the UST platform. The report also highlighted some of the Company’s recent collaborations. Earlier this year, Pressure BioSciences and RedShiftBio expressed the potential of combining their proprietary technologies to produce a new tool for the development and production of biotherapeutics. The Company also signed a worldwide, co-marketing alliance with Leica Microsystems, which integrates its Pressure Cycling Technology (“PCT”) with RedShiftBio’s laser microdissection platform. Together, both companies believe the platform provides the potential to accelerate cancer R&D using an innovative and proprietary tumor processing workflow. These encouraging results and developments, in addition to the Company’s success in developing and preparing its technologies for numerous and diverse large market opportunities worldwide, are positioning Pressure BioSciences for a strong start in 2021 and setting the Company on a path to achieve major revenue growth and profitability next year, according to Chairman of the Board Jeffrey N. Peterson. For more information, visit the company’s website at www.PressureBioSciences.com. NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

• Entered industry during pandemic with aggressive approach to target specific demographics, attract new gamers
• eSports betting increased by almost 3,000% in March 2020, 124% in April, and 36% more in May
• Gamers, seasoned gamblers and newbies brought into the platform enticed to increase participation through loyalty, gamification programs

Mobius Interactive launched three differentiated brands simultaneously in September 2020. While the gambling industry as a whole saw a decline in 2020, esports and online gaming saw a surge in users. Mobius’ three brands — Aragon Casino, Club Double and MobiusBet — target specific demographics and interests and hone in on the growing esports segment expected to reach a value exceeding $1.7 billion in 2021. The COVID-19 pandemic played a toll on gambling and betting activities in 2020 (https://ibn.fm/yU6KJ). So much so that IBISWorld projects a revenue fall for the industry of 27%. This is in large part due to the lack of spectators at live events. As spectator sporting events begin to reopen with social-distancing measures in place, the industry anticipates some recovery as companies learn to pivot and approach reopening challenges. IBISWorld projects the 2021–22 year to be strong and estimates an increase in revenue by 23.9%. While in-person spectator gambling sports such as horse racing saw a decline in revenue, esports thrived. People stuck in lockdown sought an escape and a measure of social interaction. According to the IBISWorld report, esports betting increased by 2,992% in March 2020, then another 124% in April, and 36% more in May. What began as a substitute activity looks to be quickly becoming the norm, providing an even safer alternative to social-distancing constraints placed on live events. Mobius is looking to grow through multiple touchpoints. Through targeted marketing efforts, the company is attracting newbies to the world of online gaming and seasoned gamblers. According to IBISWorld only 0.2% of adults in an April YouGov survey reported that they had started gambling for the first time at the beginning of the pandemic. Mobius is raising the stakes. A partnership with Puurl is providing the opportunity to attract players shopping online with “soft gaming.” Individuals who might not typically be attracted to the platform are enticed with the opportunity to place a bet on an object they were looking to purchase. The company is also seeking out high-value players by partnering with more than 600 VIP and Master gaming affiliates. Once a customer, seasoned or “soft,” is brought in, the platform works through loyalty and gamification programs to increase participation. Mobius may be a new company, but the company’s leadership team brings more than four decades of hands-on experience in the industry. In the last three years alone, the company’s management team is responsible for launching 30 successful products. If their track record is any indication, Mobius is worth betting on. For more information, visit the company’s website at www.MobiusInteractive.Ltd. NOTE TO INVESTORS: The latest news and updates relating to Mobius are available in the company’s newsroom at http://ibn.fm/Mobius

• VistaGen currently developing three novel drug candidates designed to treat central nervous system disorders
• Anxiety disorders have been found to affect 18.1% of the U.S. population; however, only 36.9% of those suffering receive treatment
• Prevalence of depressive disorders in U.S. workplace is estimated to result in economic impact of over $210.5 billion per annum
• COVID-19 pandemic has further exacerbated these conditions, with number of patients displaying anxiety symptoms rising by 93% YoY between January – September 2020

VistaGen Therapeutics (NASDAQ: VTGN) is a biopharmaceutical company committed to developing a new generation of medications which go beyond the standard of care for anxiety, depression, and other central nervous system (“CNS”) disorders. Anxiety disorders have been found to be the most common mental illness in the U.S., affecting 40 million adults in the United States age 18 and older, or 18.1% of the population. However, while most anxiety disorders are highly treatable, only 36.9% of those suffering receive treatment (https://ibn.fm/z00SV). Two of the most common mental health conditions, namely depression and anxiety, are estimated to cost the global economy $1 trillion each year—and these conditions have been further exacerbated during the COVID-19 pandemic (https://ibn.fm/tmPyO). A recent study carried out by Mental Health America found that the number of people looking for help with anxiety and depression has skyrocketed in 2020; between January to September 2020, the number of people screening for anxiety symptoms rose by 93% relative to 2019 while those found to have symptoms of depression rose by 62% year-on-year (https://ibn.fm/rDGWQ). Within the U.S. workforce, the prevalence of major depressive disorders (MDD) has been estimated at 7.6%, with the total economic burden now estimated to be over $210.5 billion per year. Nearly half of these costs are attributed to the work place, including absenteeism (missed days from work) as well as reduced productivity while at work, whereas 45-47% are due to direct medical costs, which are shared by employers, employees, and society (https://ibn.fm/ev3Ns). The impact of CNS-related disorders on patient lives and the wider global economy, coupled with the potential risks associated to conventional benzodiazepine drugs – the class of medicines approved to treat conditions such as anxiety, insomnia and seizures—have increased the urgent need for pharmaceutical companies to develop safer alternatives to the traditional medication available to patients today. VistaGen Therapeutics has sought to address this situation through its product portfolio, consisting of three novel drug candidates – namely, PH94B, PH10 and AV-101, which seek to target a wide variety of central nervous system (“CNS”) disorders through medications designed to present fewer side-effects relative to their commonly used peers. PH94B is a fast-acting, non-systemic and non-sedating neuroactive nasal spray which is being developed as an acute treatment of anxiety in adults afflicted with social anxiety disorder (“SAD”). It has been designed to displace benzodiazepines – which have recently been required by the U.S. Food and Drug Administration to describe the risks of abuse, misuse, addiction, physical dependence and withdrawal reactions consistent to all medicines in this class (https://ibn.fm/wgF1B). PH10 is an investigational synthetic neuroactive nasal spray in development as a potential rapid-onset therapeutic alternative in a wide range of depression-related disorders. Mental health conditions have been found to have a substantial effect on all areas of life, including socially and economically. Through the development of its three novel drug candidates, VistaGen Therapeutics has sought to address the growing need for safe and effective treatments to a disease whose spread had gone widely unchecked in recent years. NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

• Recent study reports that consumers are opting for single-serve beverages; bottled water outperforms carbonated beverages
• WTER’s flagship product — Alkaline88 — now available in easy-to-carry, two-liter single-serve bottles
• Company’s A88 flavor-infused water offering gaining significant market share, available in growing number of spaces

A growing number of consumers who drink and snack throughout the day are turning to single-serve, ready-to-drink beverages, often found most easily at c-stores, according to a recent Shop Association report (https://ibn.fm/Q5Hw7). Recognizing the market opportunity, The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER) recently launched a new 2-liter single-serve option to meet that increased customer demand (https://ibn.fm/aysjl). “Overall, the beverage industry is positioned to remain strong throughout the coming years with bottled water outperforming carbonated beverages,” reported the Shop Association study, which also noted that convenience is a key driver in the segment growth. “A recent global Packaging market research study from the Association for Packaging and Processing technologies found that customers tend to pick up grab-and-go foods for purchase as an impulse. Retailers and brands can capitalize on this impulse spending while finding ways to implement environmentally friendly messages and customizable elements into foodservice packaging. Grab-and-go programs for a product in a growing category is one way to increase incremental sales for both brands and retailers.” Committed to meet the needs of consumers and retailers alike, WTER unveiled its flagship product — Alkaline88(R) — in new, easy-to-carry, two-liter bottles, available for purchase alone or in a six pack. “This unique six pack complements our existing line-up, especially our single-serve offerings, which continue to do well in the current environment,” said The Alkaline Water Company’s president and CEO Ricky Wright. “The two-liter format is extremely popular in the carbonated soft drinks segment but virtually nonexistent in the bottled water category.” With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and perfectly represents the company’s trademarked Clean Beverage label. In addition to Alkaline88 and in another show of its astute awareness of consumer demand and interest, The Alkaline Water Company also offers A88 Infused(TM). Available in seven all-natural flavors (with new flavors on the horizon), the flavor-infused water offering is gaining significant market share and is available in a growing number of spaces (https://ibn.fm/ndOgp). “Demand for our single-serve offerings are at an all-time high, and we are rapidly growing shelf space for our A88 Infused flavored waters,” stated Wright. “Our channel partners are some of the leading players in the all-natural vertical and give us a reach into nearly 40,000 retailers nationwide. Our sales team is working closely with our partners to create ‘speed to market’ programs, including promotion and incentives to drive further momentum. We are doing a great job creating new leads, and currently, our flavors are carried by or have placement commitments from nearly 13,200 stores across the U.S. . . .Our A88 Infused brand is now available in some of the top supermarkets, retailers, and wholesalers, and we expect this trend to accelerate throughout our fiscal year.” Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88, is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. In addition to its A88 Infused(TM) water line, the company also recently launched A88CBD, a line of CBD-infused beverages.  For its topical and ingestible offerings, A88 Infused products include both the company’s lab-tested, hemp extract salves, balms, lotions, essential oils, and bath salts, along with hemp extract powder packs, oil tinctures, capsules, and gummies. For more information, visit the company’s websites at www.A88CBD.com and www.TheAlkalineWaterCo.com. NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://ibn.fm/WTER